用AI驱动的模型预测VA-ECMO患者的死亡风险:一个多中心队列研究
Shuai Wang1, Sichen Tao2, Ying Zhu1
1Department of Critical Care, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, China.
Scientific reports
|March 26, 2025
概括
这项研究开发了一种人工智能模型,用于预测静脉动脉外体膜氧化 (VA-ECMO) 断奶的患者的28天死亡风险. 该eCMoML模型显示出高准确性和通用性,有助于临床决策,以获得更好的患者结果.
科学领域:
- 关键护理医学 关键护理医学
- 医疗保健中的人工智能
- 生物医学工程 生物医学工程
背景情况:
- 静脉动脉外体膜氧化 (VA-ECMO) 对重症患者至关重要,但存在高死亡风险.
- 改善VA-ECMO断奶后死亡率的预测对于临床决策和患者管理至关重要.
研究的目的:
- 开发和验证一种非侵入性,支持人工智能的模型,用于预测VA-ECMO断奶后28天死亡风险.
- 确定关键的预测特征,并评估开发模型的临床效用.
主要方法:
- 一个多中心的回顾性队列研究,涉及五家医院的225名患者.
- 开发和比较使用25个选定的患者特征的10个机器学习模型.
- 使用内部和外部队列验证,通过AUROC,SHAP和决策曲线分析评估绩效.
主要成果:
- 随机森林模型 (eCMoML) 显示出优异的预测性能,AUROC值为1.00 (训练),1.00,0.97和0.93 (验证队列).
- 尽管训练数据有限,但该模型显示出高准确性,可概括性和可靠性.
- SHAP分析发现了重要的预测特征,决策曲线分析证实了临床效用.
结论:
- 该eCMoML模型提供了一个快速,稳定和准确的工具,用于预测VA-ECMO断奶后28天死亡率.
- 这种人工智能驱动的方法可以显著提高临床决策,预后评估和治疗优化.
- 该模型有望改善接受VA-ECMO治疗的患者的生存率.
相关概念视频
Cancer Survival Analysis
313
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
313
Relative Risk
104
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
104
Assumptions of Survival Analysis
76
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
76
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
37
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
37
Statistical Methods for Analyzing Epidemiological Data
266
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
266
Kaplan-Meier Approach
67
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
67


